TMC Life Sciences (0101) Fundamentals 2026 — P/E 54.0x, Revenue Analysis | SniperIQ
TMC Life Sciences (0101) is a MY-listed Healthcare company in Medical - Care Facilities with a market capitalization of RM819M, trading at RM0.47 on the KLS. This SniperIQ fundamentals page covers TMC Life Sciences's valuation (P/E 54.0x, P/B 0.9x), profitability (net margin 3.9%), revenue (RM346M in FY2024), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is TMC Life Sciences's market cap?
TMC Life Sciences (0101) has a market capitalization of approximately RM819M, trading at RM0.47 on the KLS. Market cap moves with the live share price.
What is TMC Life Sciences's P/E ratio?
TMC Life Sciences's trailing twelve-month P/E ratio is 54.0x, with a price-to-book (P/B) of 0.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is TMC Life Sciences?
TMC Life Sciences runs a net profit margin of 3.9%, a gross margin of 53.7%, and an operating margin of 5.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does TMC Life Sciences generate?
TMC Life Sciences reported revenue of RM346M for fiscal year 2024, with net income of RM4M and earnings per share (EPS) of 0.0021. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does TMC Life Sciences pay a dividend?
TMC Life Sciences offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is TMC Life Sciences financially healthy?
TMC Life Sciences carries a debt-to-equity ratio of 0.18x and a current ratio of 1.82x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is TMC Life Sciences a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TMC Life Sciences (0101) the key facts are: market cap RM819M, P/E 54.0x, revenue RM346M, 52-week range 0.38-0.575. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track TMC Life Sciences's full fundamentals live
Get TMC Life Sciences's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.